Detailed structural analysis of amyloidogenic wild-type transthyretin using a novel purification strategy and mass spectrometry
- PMID: 17261023
- DOI: 10.1021/ac061546s
Detailed structural analysis of amyloidogenic wild-type transthyretin using a novel purification strategy and mass spectrometry
Abstract
Wild-type transthyretin (TTR), normally a soluble plasma-circulating protein, can be amyloidogenic, i.e., form tissue-deposited fibrillar material in the extracellular matrix of various organs throughout the body. Senile systemic amyloidosis (SSA) is one such pathology and features TTR-containing amyloid deposits that are found primarily in the heart. The cause for this transition from soluble to insoluble protein in SSA is yet to be determined as specific structural features that might favor TTR fibrillogenesis have not yet been identified. The precise characterization of ex vivo fibril deposits might provide insight, but structural analyses of TTR from amyloid deposits have been hindered thus far by the lack of purification strategies that overcome the insolubility of the tissue-derived protein without degrading it. Consequently, the true biochemical nature of deposited TTR remains in question. In this study, we provide detailed analyses of both the soluble (serum) and deposited (tissue) forms of TTR from cases of SSA. In the serum, a distribution of mixed disulfides, specifically S-sulfonated and S-cysteinylated forms of TTR, as well as the unmodified protein were identified. The relative levels of the three TTR species in the SSA group were comparable to amounts present in sera from age-matched control groups. For characterization of the amyloid deposited TTR, we investigated cardiac tissue samples obtained from three separate cases of SSA. We report a novel chromatographic purification strategy performed under nonreducing conditions (to maintain cysteine disulfide status) and the use of this procedure in conjunction with detailed mass spectrometric analysis of TTR from the amyloid deposits. A series of C-terminal TTR fragments with N-termini ranging from amino acids 46 to 55 were identified. We also determined that the deposits in all samples contained Cys10 disulfide-linkedhomodimers composed of full-length TTR monomers. This last finding suggests an important role for Cys10 conjugation in the transition from soluble TTR to the pathological amyloid fibril.
Similar articles
-
Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology.J Pathol. 2005 Jun;206(2):224-32. doi: 10.1002/path.1759. J Pathol. 2005. PMID: 15810051
-
Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis.Lab Invest. 1995 Nov;73(5):703-8. Lab Invest. 1995. PMID: 7474944
-
Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions.Biochemistry. 2003 Jul 29;42(29):8756-61. doi: 10.1021/bi030077a. Biochemistry. 2003. PMID: 12873136
-
Review: TTR amyloidosis-structural features leading to protein aggregation and their implications on therapeutic strategies.J Struct Biol. 2000 Jun;130(2-3):290-9. doi: 10.1006/jsbi.2000.4273. J Struct Biol. 2000. PMID: 10940233 Review.
-
[Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know].Ital Heart J Suppl. 2002 Jun;3(6):590-7. Ital Heart J Suppl. 2002. PMID: 12116807 Review. Italian.
Cited by
-
Structural Characterization of Cardiac Ex Vivo Transthyretin Amyloid: Insight into the Transthyretin Misfolding Pathway In Vivo.Biochemistry. 2020 May 19;59(19):1800-1803. doi: 10.1021/acs.biochem.0c00091. Epub 2020 Apr 30. Biochemistry. 2020. PMID: 32338497 Free PMC article.
-
Disruption of the CD Loop by Enzymatic Cleavage Promotes the Formation of Toxic Transthyretin Oligomers through a Common Transthyretin Misfolding Pathway.Biochemistry. 2020 Jun 30;59(25):2319-2327. doi: 10.1021/acs.biochem.0c00079. Epub 2020 Jun 14. Biochemistry. 2020. PMID: 32500705 Free PMC article.
-
Experimentally derived structural constraints for amyloid fibrils of wild-type transthyretin.Biophys J. 2011 Nov 16;101(10):2485-92. doi: 10.1016/j.bpj.2011.10.009. Epub 2011 Nov 15. Biophys J. 2011. PMID: 22098747 Free PMC article.
-
Toxic Misfolded Transthyretin Oligomers with Different Molecular Conformations Formed through Distinct Oligomerization Pathways.Biochemistry. 2022 Nov 1;61(21):2358-2365. doi: 10.1021/acs.biochem.2c00390. Epub 2022 Oct 11. Biochemistry. 2022. PMID: 36219173 Free PMC article.
-
Differential modification of Cys10 alters transthyretin's effect on beta-amyloid aggregation and toxicity.Protein Eng Des Sel. 2009 Aug;22(8):479-88. doi: 10.1093/protein/gzp025. Epub 2009 Jun 23. Protein Eng Des Sel. 2009. PMID: 19549717 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous